Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

Author： Roehrborn C.G.   Boyle P.   Nickel J.C.   Hoefner K.   Andriole G.   the ARIA3001 ARIA3002 and ARIA3003 Study Investigators  

Publisher： Elsevier

ISSN： 0090-4295

Source： Urology, Vol.60, Iss.3, 2002-09, pp. : 434-441

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Safety and Tolerability of the Dual 5 -Reductase Inhibitor Dutasteride in the Treatment of Benign Prostatic Hyperplasia

By Andriole G.L.   Kirby R.  

European Urology, Vol. 44, Iss. 1, 2003-07 ,pp. : 82-88

Elsevier

Access to resources Recommend Favorite

Effect of the dual 5 alpha-reductase inhibitor dutasteride on endocrine parameters and prostate volume

By Roehrborn C.   Andriole G.   Boyle P.   Hofner K.  

European Urology Supplements, Vol. 1, Iss. 1, 2002-01 ,pp. : 107-107

Elsevier

Access to resources Recommend Favorite

Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia

By Kaplan S.A.   Holtgrewe H.L.   Bruskewitz R.   Saltzman B.   Mobley D.   Narayan P.   Lund R.H.   Weiner S.   Wells G.   Cook T.J.   Meehan A.   Waldstreicher J.   for the Proscar Long-Term Efficacy and Safety Study Group  

Urology, Vol. 57, Iss. 6, 2001-06 ,pp. : 1073-1077

Elsevier

Access to resources Recommend Favorite

Dihydrotestosterone and the concept of 5α-reductase inhibition in human benign prostatic hyperplasia

By Bartsch G.   Rittmaster R.   Klocker H.  

World Journal of Urology, Vol. 19, Iss. 6, 2002-04 ,pp. : 413-425

Springer Publishing Company

Access to resources Recommend Favorite

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia

By Lepor H.  

Urology, Vol. 45, Iss. 3, 1995-03 ,pp. : 406-413

Elsevier

Access to resources Recommend Favorite